For many, the name Michael Milken is synonymous with avarice and conspicuous consumption that characterized Wall Street speculators of the 1980s. However, in the time since his release from federal prison after pleading guilty to securities fraud, serving a two-year sentence, and paying more than $1 billion in fines and settlements, the 48-year-old former junk bond king has been working toward being more closely associated with a cure for prostate cancer.

The foundation Milken started in 1993, the Association for the Cure of Cancer of the Prostate (CaP CURE), has approached this ambitious goal from two directions: funding a wide range of peer-reviewed prostate cancer research projects and bringing investigators, politicians, and businesspeople together to bring more attention and money to fighting the disease. CaP CURE is now the second-largest funder of prostate cancer research in the United States, foundation officials claim, behind only the National Cancer Institute (NCI).


Interested in reading more?

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?